Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 9/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.79 |
| ▸ | TP53 | P04637 | 3/20 | 0.79 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.79 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.79 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | THRB | P10828 | 5/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1649072 | 1.00 | TSHR (0.79) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL9421560 | 1.00 | TSHR (0.79) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL238289 | 1.00 | TSHR (0.79) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL828427 | 1.00 | TSHR (0.79) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL11762916 | 1.00 | TSHR (0.79) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL10150594 | 1.00 | TSHR (0.79) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL19583211 | 0.94 | TSHR (0.70) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL12701599 | 0.89 | TSHR (1.00) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL4602612 | 0.89 | TSHR (1.00) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL8636795 | 0.89 | TSHR (1.00) | TSHRALDH1A1TP53HIF1AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329377-B2 | Imide compound and chemically amplified resist composition containing the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-12-11 | — | — | US | disclosed |
| US-8173350-B2 | Oxime compound and resist composition containing the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-05-08 | — | — | US | disclosed |
| US-20100028807-A1 | Imide Compound and Chemically Amplified Resist Composition Containing The Same | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 2010-02-04 | — | — | US | disclosed |
| US-20100021847-A1 | Oxime Compound and Resist Composition Containing the Same | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 2010-01-28 | — | — | US | disclosed |
| EP-0735076-B1 | Process for the production of star-like or comb-like branched aliphatic polyamino compound and curable resin composition | TOYO INK MFG CO (JP) | 2004-01-02 | — | — | EP | disclosed |
| US-5705602-A | Process for the production of star-like or comb-like branched aliphatic polyamino compound and curable resin composition | TOYO INK MANUFACTURING CO., LTD. (JP) | 1998-01-06 | — | — | US | disclosed |
| EP-0735076-A1 | Process for the production of star-like or comb-like branched aliphatic polyamino compound and curable resin composition | TOYO INK MANUFACTURING CO., LTD. (JP) | 1996-10-02 | — | — | EP | disclosed |
| US-5290834-A | Method for controlling elution rate of agent | ROHM & HAAS COMPANY (US) | 1994-03-01 | — | — | US | disclosed |
| US-4310397-A | SUSTAINED RELEASE; PREPARED BY IRRADIATION POLYMERIZATION | JAPAN ATOMIC ENERGY RESEARCH INSTITUTE (JP) | 1982-01-12 | — | — | US | disclosed |
| US-4194066-A | POLYMERIZING POLYOXYALKYLENE GLYCOL (METH)ACRYLATES | JAPAN ATOMIC ENERGY RESEARCH INSTITUTE (JP) | 1980-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100028807-A1 | Imide Compound and Chemically Amplified Resist Composition Containing The Same | IGF1R, CCNA1, MYC | TSHR 2519/4885ALDH1A1 386/4885TP53 1553/4885 |
| US-20100021847-A1 | Oxime Compound and Resist Composition Containing the Same | CYC1, UQCRB, CBR1 | TSHR 841/4885ALDH1A1 1280/4885TP53 3975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.